Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Interleukin-37 (IL-37) is a potent anti-inflammatory cytokine belonging to the IL-1 family that acts as a natural suppressor of innate and adaptive immunity. Unlike most IL-1 family members, IL-37 functions to dampen inflammatory responses by translocating to the nucleus to inhibit the transcription of pro-inflammatory genes and by signaling through a cell-surface receptor complex. Specifically, IL-37 binds to the interleukin-18 receptor alpha (IL-1R5) and recruits the single Ig IL-1-related receptor (IL-1R8/SIGIRR) to initiate an inhibitory signaling cascade. This mechanism suppresses the production of various pro-inflammatory cytokines, including IL-1, IL-6, and TNF-alpha. IL-37 is being investigated for its potential to restore immune homeostasis in autoimmune and inflammatory conditions, such as inflammatory bowel disease (IBD), where it has been shown to stabilize regulatory T-cells (Tregs) and preserve FOXP3 expression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on interleukin-37.